Answers are grounded in this paper and cite their sources.
This monograph establishes a rigorous technical, thermodynamic, and capital-allocation framework evaluating the technology gaps and investment priorities in clinical medical AI, centering on three structural axes: (1) Non-Contrast CT to Contrast-Enhanced CT "Virtual Contrast" synthesis, (2) dedicated 3D Swin-UNETR ASIC hardware acceleration, and (3) structural Return on Investment (ROI) asymmetry across hospital reimbursement and liability regimes. While 3D shifted-window transformer architectures (Swin-UNETR) demonstrate high structural fidelity in volumetric feature extraction from routine non-contrast CT (NCCT) scans, executing high-resolution 3D window self-attention on general-purpose GPUs incurs severe memory-bandwidth bottlenecks and latency penalties in acute triage workflows. We formulate a deterministic custom ASIC dataflow architecture tailored for 3D Swin-UNETR volumetric patch partitioning, on-chip SRAM cyclic window shifting, and cryptographic zero-knowledge state verification (QFS-zkVM over the 64-bit Goldilocks prime field F_p, p = 2^64 - 2^32 + 1) to eliminate stochastic hallucination risks in synthetic vascular enhancement. Furthermore, we quantify the clinical and economic ROI asymmetry between capital-intensive foundational model training and deterministic edge-ASIC deployment—accounting for contrast-induced nephropathy (CIN) mitigation, iodinated contrast supply-chain volatility, radiology throughput gains, and statutory Human-in-Command (HIC) fiduciary liability boundaries. [概要(日本語)] 本論文(モノグラフ)は、医療AIにおける技術的ギャップと資本配分・投資優先順位について、①単純CTからの仮想造影(Virtual Contrast)生成技術、②3D Swin-UNETR専用ASICによるハードウェア・アクセラレーション、③臨床導入におけるROI(投資対効果)の非対称性という3つの構造軸から定量的・数理的に解明するものである。単純CT(NCCT)から造影CT相当の血行動態・病変コントラストを再構成する「Virtual Contrast」において、3次元Swin-UNETRアーキテクチャは高い空間特徴抽出能力を持つ一方、汎用GPU上での3D Shifted-Window Self-Attention演算は深刻なメモリ帯域ボトルネックと推論遅延を引き起こす。本研究では、3次元ボクセルパッチ分割とオンチップSRAM巡回ウィンドウシフトをハードウェアレベルで最適化したSwin-UNETR専用ASICアーキテクチャを設計するとともに、生成画像の確率的ハルシネーション(偽陽性・偽陰性造影効果)を排除するための決定論的暗号検証(64-bit Goldilocks素体 F_p 上のQFS-zkVMおよびHuman-in-Command [HIC] 統治原則)を統合する。さらに、造影剤腎症(CIN)リスクの回避、ヨード造影剤サプライチェーンの逼迫対策、読影スループット向上、および医療過誤責任(Caremark監視義務・製造物責任)の非対称性を踏まえた最適投資優先順位を導出する。 [License & Strict No-Learn Covenant] Creative Commons Attribution 4.0 International (CC BY 4.0) with Strict No-Learn Covenant (NLL-v1.0-2026). Unauthorized ingestion, scraping, weight-updating, distillation, or machine-learning training by any AI system or platform provider without explicit prior written agreement and direct financial compensation is strictly prohibited.
No takes yet. Share an insight, caveat, or question.
Yoko(洋子) Hasebe(長谷部) (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: